Summary
Medtronic plc reported solid financial results for the nine months ended January 24, 2025, with net sales reaching $24.6 billion, a 4% increase compared to the prior year, driven by growth across most business segments, particularly in Cardiac Rhythm & Heart Failure, Diabetes, and Neuromodulation. Diluted earnings per share (EPS) for the nine-month period were $2.79, a significant increase from $2.27 in the prior year, reflecting improved profitability. The company generated strong operating cash flow of $4.5 billion and free cash flow of $3.1 billion for the nine months, underscoring its financial health and ability to fund operations and shareholder returns. Medtronic's liquidity remains robust, with $1.2 billion in cash and cash equivalents and $6.7 billion in current investments as of January 24, 2025. Key operational highlights include continued strong performance in the Cardiovascular and Neuroscience portfolios, with notable growth in specific product lines such as the MiniMed 780G insulin pump system and the Inceptiv spinal cord stimulator. The company also reported progress in new product adoption, such as the Evolut FX+ TAVR system and the Aurora Extravascular ICD system. While facing some headwinds in Medical Surgical segments, the overall sales trajectory and profitability improvements indicate a positive operational performance. Investors should monitor Medtronic's ongoing product innovation, geographic expansion, and its ability to navigate competitive pressures and macroeconomic factors, as highlighted in the MD&A, which could influence future performance.
Financial Highlights
53 data points| Revenue | $8.29B |
| Cost of Revenue | $2.78B |
| Gross Profit | $5.51B |
| SG&A Expenses | $2.72B |
| Operating Income | $1.65B |
| Net Income | $1.29B |
| EPS (Basic) | $1.01 |
| EPS (Diluted) | $1.01 |
| Shares Outstanding (Basic) | 1.28B |
| Shares Outstanding (Diluted) | 1.29B |
Key Highlights
- 1Net sales increased by 4% to $24.6 billion for the nine months ended January 24, 2025, driven by broad-based growth across key segments.
- 2Diluted earnings per share (EPS) rose to $2.79 for the nine months ended January 24, 2025, up from $2.27 in the prior year, indicating improved profitability.
- 3Operating cash flow strengthened to $4.5 billion for the nine months ended January 24, 2025, with free cash flow reaching $3.1 billion.
- 4The Cardiovascular segment saw a 5% increase in net sales for the nine months, driven by Cardiac Ablation Solutions, Structural Heart, and Cardiac Pacing Therapies.
- 5The Neuroscience segment reported a 5% increase in net sales for the nine months, primarily due to growth in Neuromodulation, Spine and Biologics, and Neurosurgery.
- 6The Diabetes segment experienced an 11% increase in net sales for the nine months, attributed to strong adoption of the MiniMed 780G AID system and international CGM growth.
- 7Medtronic maintained a strong liquidity position with $1.2 billion in cash and cash equivalents and $6.7 billion in current investments as of January 24, 2025.